Jefferies downgraded Cerevel Therapeutics (CERE) to Hold from Buy with a price target of $45, up from $40, after AbbVie (ABBV) announced plans to acquire Cerevel for $45.00 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CERE:
